Muscle Invasive Urothelial Carcinoma clinical trials

Explore recruiting muscle invasive urothelial carcinoma clinical trials.

Recruiting muscle invasive urothelial carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Muscle Invasive Urothelial Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Prospective randomised study of the impact of preoperative administration of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle invasive urothelial carcinoma

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)

France, Poland, Germany, Spain, Italy, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Germany, Netherlands, Spain, Belgium, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE UROTHELIAL CARCINOMA

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non- Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette- Guérin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy

Germany, France, Netherlands, Portugal, Spain, Belgium +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy

Austria, Czechia, France, Germany, Spain, Portugal +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Muscle Invasive Urothelial Carcinoma trials by city

Muscle Invasive Urothelial Carcinoma in Toronto Muscle Invasive Urothelial Carcinoma in Vancouver Muscle Invasive Urothelial Carcinoma in Montreal Muscle Invasive Urothelial Carcinoma in Calgary Muscle Invasive Urothelial Carcinoma in Edmonton Muscle Invasive Urothelial Carcinoma in Ottawa Muscle Invasive Urothelial Carcinoma in Winnipeg Muscle Invasive Urothelial Carcinoma in Quebec City Muscle Invasive Urothelial Carcinoma in Hamilton Muscle Invasive Urothelial Carcinoma in Kitchener Muscle Invasive Urothelial Carcinoma in London Muscle Invasive Urothelial Carcinoma in Halifax Muscle Invasive Urothelial Carcinoma in New York Muscle Invasive Urothelial Carcinoma in Los Angeles Muscle Invasive Urothelial Carcinoma in Chicago Muscle Invasive Urothelial Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease